Oncopeptides is a pharmaceutical company focused on the development of therapies for difficult-to-treat haematological cancers. The company is focusing the clinical development of the lead candidate melflufen in multiple myeloma. Melflufen is currently being tested in late-stage clinical settings including the phase III study OCEAN. The company plans to during H1 2020 file a New Drug Application for accelerated approval for the treatment of patients with triple-class refractory multiple myeloma.
Oncopeptides operates from the headquarters in Stockholm and is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. Industrifonden is founding investor and currently the second largest owner.